Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Johnson & Johnson is reportedly set to acquire Intra-Cellular Therapies for around $10 billion.
Johnson & Johnson is reportedly in talks to acquire Intra-Cellular Therapies for around $10 billion, focusing on the latter's treatments for central nervous system disorders.
The potential deal could be finalized as soon as this week, marking J&J's return to major acquisitions following a 2024 slump in healthcare transactions.
Intra-Cellular's shares have risen about 40% in the last year.
45 Articles
Johnson & Johnson, según se informa, adquirirá terapias intra-células por alrededor de $10 mil millones.